Iovance is focused on the development and commercialization of autologous tumor Infiltrating lymphocyte (TIL) Therapies that amplify the body’s own immune response in order to eradicate solid tumors. Iovance is conducting multiple Phase 2 trials with its investigational therapies and has reported clinically meaningful responses in several cancers.